RNS Number : 2716X
Hikma Pharmaceuticals Plc
24 April 2023
 

 

Hikma Pharmaceuticals PLC - EIP Vesting

LONDON, 24 April 2023: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 25 February 2021 under the 2014 Executive Incentive Plan ("EIP") Element B and 27 February 2020 under the EIP Element C.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman and Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 34,827

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 34,827

 £0.00

 £0.00

e)

Date of the transaction

17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 27,057

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 27,057

 £0.00

 £0.00

e)

Date of the transaction

17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

 

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 24,319

d)

Aggregated information

-       Volume

-       Price

 

Total

 

 

 24,319

 £0.00

 £0.00

e)

Date of the transaction

17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 18,831

d)

Aggregated information

-       Volume

-       Price

 

Total

 

 

 18,831

 £0.00

 £0.00

e)

Date of the transaction

17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

 

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 Riad Mishlawi

2

Reason for the notification

a)

Position/status

 PDMR

b)

Initial notification /Amendment

 Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Hikma Pharmaceuticals PLC

b)

LEI

 549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

 Description: Ordinary shares of 10 pence each (Shares)

 ID Code: GB00B0LCW083

b)

Nature of the transaction

 Shares acquired from the vesting of conditional awards on
 17 April 2023 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

 Price(s): £nil

 Volume(s): 20,285

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 20,285

 £0.00

 £0.00

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

 London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

 Description: Ordinary shares of 10 pence each (Shares)

 ID Code: GB00B0LCW083

b)

Nature of the transaction

 Shares acquired from the vesting of conditional awards on
 17 April 2023 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

 Price(s): £nil

 Volume(s): 22,437

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 22,437

 £0.00

 £0.00

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

 London Stock Exchange (XLON)

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 Majda Labadi

2

Reason for the notification

a)

Position/status

 PDMR

b)

Initial notification /Amendment

 Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Hikma Pharmaceuticals PLC

b)

LEI

 549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

 Description: Ordinary shares of 10 pence each (Shares)

 ID Code: GB00B0LCW083

b)

Nature of the transaction

 Shares acquired from the vesting of conditional awards on
 17 April 2023 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

 Price(s): £nil

 Volume(s): 11,205

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 11,205

 £0.00

 £0.00

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

 London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

 Description: Ordinary shares of 10 pence each (Shares)

 ID Code: GB00B0LCW083

b)

Nature of the transaction

 Shares acquired from the vesting of conditional awards on
 17 April 2023 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

  Price(s): £nil

  Volume(s): 10,690

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 10,690

 £0.00

 £0.00

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 Shares acquired from the vesting of conditional awards on
 17 April 2023 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 17,307

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 17,307

 £0.00

 £0.00

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 Shares acquired from the vesting of conditional awards on
 17 April 2023 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 17,007

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 17,007

 £0.00

 £0.00

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 17,390

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 17,390

 £0.00

 £0.00

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 17,180

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 17,180

 £0.00

 £0.00

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

 

Brian Hoffmann

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Brian Hoffmann

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element B. 4,436 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 7,683

 

Price(s): £18.065

Volume(s): 4,436

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 12,119

 £18.065

 £80,136.34

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element C. 4,378 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 7,584

 

Price(s): £18.065

Volume(s): 4,378

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 11,962

 £18.065

 £79,088.57

e)

Date of the transaction

 17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)




 

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element B.  3,990 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 4,823

 

Price(s): £18.065

Volume(s): 3,990

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 8,813

 £18.065

 £72,079.35

e)

Date of the transaction

17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element C 4,017 Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 4,857

 

Price(s): £18.065

Volume(s): 4,017

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 8,874

 £18.065

 £72,567.105

e)

Date of the transaction

17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

 

Hussein Arkhagha

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Hussein Arkhagha

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 April 2023 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 7,867

d)

Aggregated information

-       Volume

-       Price

 

-       Total

 

 

 7,867

 £0.00

 £0.00

e)

Date of the transaction

17 April 2023

f)

Place of the transaction

London Stock Exchange (XLON)

 

Hussein Arkhagha
Chief Counsel and Company Secretary

+44 (0) 20 7399 2760

24 April 2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBUGDSXBDDGXS